...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: 50/50 at best on Zen being sold this year IMO..

"Some alternatives may not be palatable but he has manoeuvered himself in between the Devil and the deep blue sea.

I think that he is positively Trumpian about getting the glory for a big deal, while his shareholders and their equity withers away."

He should step down from both companies - IMO hetruly lacks one of the most important requirements of being a successful CEO, humility.

Share
New Message
Please login to post a reply